References
- Bodey G P, Buckley M, Sathe Y S, Freireich E J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64: 328–340
- Gabrilove J. The development of granulocyte colony-stimulating factor in its various clinical applications. Blood. 1992; 80: 1382–1385
- Morstyn G, Campbell L, Souza L M. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; i: 667–672
- Lindemann A, Herrmann F, Oster W. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood. 1989; 74: 2644–2651
- Morstyn G, Campbell L, Lieschke G. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol. 1989; 7: 1554–1562
- Eguchi K, Sasaki S, Tamura T. Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN 8601) in patients with advanced malignancy. Cancer Res. 1989; 49: 5221–5224
- Ohno R, Tomonaga M, Ohshima T. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Int J Hematol. 1993; 58: 73–81
- Bokemeyer C, Schmoll H J, Metzner B. Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. Ann Hematol. 1993; 67: 75–79